Anti-VEGF Treatment Strategies for Wet AMD

Jaclyn L Kovach, Stephen G Schwartz, Harry W Flynn Jr, Ingrid U Scott, Jaclyn L Kovach, Stephen G Schwartz, Harry W Flynn Jr, Ingrid U Scott

Abstract

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

Figures

Figure 1
Figure 1
Ranibizumab is a recombinant humanized monoclonal antibody fragment. Bevacizumab is a recombinant humanized IgG antibody. Both bind to and inhibit all biologically active forms of VEGF-A and are derived from the same mouse monoclonal antibody. Ranibizumab has been genetically engineered to bind with higher affinity than bevacizumab (see [8]).
Figure 2
Figure 2
(a) A binding domain of VEGFR1 and VEGFR2 are fused to create 2 dual-domain arms for each VEGF Trap-Eye molecule. (b) The Fc portion of the IgG is fused to the two dual-domain arms to create the VEGF Trap-Eye molecule (see [9]).

References

    1. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological Reports. 2006;58(3):353–363.
    1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews. 2004;25(4):581–611.
    1. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116(10):S1–S7.
    1. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of Ophthalmology. 2002;120(3):338–346.
    1. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Archives of Ophthalmology. 2005;123(4):509–516.
    1. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine. 2004;351(27):2805–2816.
    1. VISION Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508–1521.
    1. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. New England Journal of Medicine. 2006;355(14):1409–1412.
    1. Sharma S, Kaiser PK. Update on VEGF Trap-Eye clinical trials. Retinal Physician. November 2010
    1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery. 2004;3(5):391–400.
    1. Tolentino MJ, Husain D, Theodosiadis P, et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Archives of Ophthalmology. 2000;118(1):78–84.
    1. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113(11):2002–2011.
    1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery Lasers and Imaging. 2005;36(4):331–335.
    1. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;114(2):363–400.
    1. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870.
    1. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina. 2007;27(9):1196–1200.
    1. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab. Ophthalmology. 2007;114(12):2179–2182.
    1. Pegaptanib Product Information.
    1. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Investigative Ophthalmology and Visual Science. 2005;46(2):726–733.
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1419–1431.
    1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1432–1444.
    1. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology. 2010;150(3):315–324.
    1. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. the EXCITE study. Ophthalmology. 2010;118:831–839.
    1. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. American Journal of Ophthalmology. 2009;148(1):1–3.
    1. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731–1739.
    1. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology. 2010;94(1):2–13.
    1. Ranibizumab safe and effective over long term in HORIZON extension study. Ophthalmology Times. 2009
    1. Engelbert M, Zweifel SA, Freund KB. "treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29(10):1424–1431.
    1. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2010;31(1):26–30.
    1. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology. 2010;117(11):2134–2140.
    1. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. British Medical Journal. 2010;340(7761):p. 1398. Article ID c2459.
    1. Fong KCS, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clinical and Experimental Ophthalmology. 2008;36(8):748–755.
    1. Mekjavic PJ, Kraut A, Urbancic M. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmologica. 2009;89(7):647–653.
    1. Leydolt C, Michels S, Prager F, et al. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmologica. 2010;88(5):594–600.
    1. Luu ST, Gray T, Warrier SK, et al. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clinical and Experimental Ophthalmology. 2010;38(7):659–663.
    1. Arevalo JF, Snchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the pan-american collaborative retina study. Ophthalmology. 2010;117(10):1974–1981.
    1. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. American Journal of Ophthalmology. 2009;148(1):59–65.
    1. Treat-and-extend therapy a popular, cost-effective approach to treating neovascular AMD. PCONSuperSite. 2011
    1. Martin DF, Maguire MG, Ying G-S, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2011;364(20):1897–1908.
    1. Rosenfeld PJ. Bevacizumab versus ranibizumab—the verdict. New England Journal of Medicine. 2011;364(20):1966–1967.
    1. Slakter JS. What to do when anti-VEGF therapy fails. Retinal Physician. 2010
    1. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. British Journal of Ophthalmology. 2009;93(5):610–613.
    1. Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114(12):2168–2173.
    1. Nguyen QD, Heier J, Brown D, et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF-Trap-Eye in wet AMD: one-year results of the VIEW-1 study. In: Proceedings of the Association for Research in Vision and Ophthalmology; 2011; Fort Lauderdale, Fla, USA.
    1. Schmidt-Erfurth U, Chong V, Kirchhof B, et al. Primary results of an international phase III study using intravitreal VEGF Trap-Eye compared to ranibizumab in patients with wet AMD (VIEW 2). In: Proceedings of the Association for Research in Vision and Ophthalmology; 2011; Fort Lauderdale, Fla, USA.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa